Delivering influenza vaccine to pregnant women.
Identifieur interne : 000865 ( Main/Exploration ); précédent : 000864; suivant : 000866Delivering influenza vaccine to pregnant women.
Auteurs : Allison L. Naleway [États-Unis] ; Wendy J. Smith ; John P. MulloolySource :
- Epidemiologic reviews [ 0193-936X ] ; 2006.
Descripteurs français
- KwdFr :
- Accessibilité des services de santé, Canada, Complications de la grossesse et maladies infectieuses (), Femelle, Grippe humaine (), Grossesse, Humains, Prise en charge prénatale, Résultat thérapeutique, Sécurité, Vaccination (), Vaccination (effets indésirables), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (ressources et distribution), États-Unis d'Amérique, Évaluation des risques.
- MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Vaccination, Vaccins antigrippaux.
- ressources et distribution : Vaccins antigrippaux.
- Accessibilité des services de santé, Canada, Complications de la grossesse et maladies infectieuses, Femelle, Grippe humaine, Grossesse, Humains, Prise en charge prénatale, Résultat thérapeutique, Sécurité, Vaccination, États-Unis d'Amérique, Évaluation des risques.
English descriptors
- KwdEn :
- Canada, Female, Health Services Accessibility, Humans, Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (supply & distribution), Influenza, Human (prevention & control), Pregnancy, Pregnancy Complications, Infectious (prevention & control), Prenatal Care, Risk Assessment, Safety, Treatment Outcome, United States, Vaccination (adverse effects), Vaccination (statistics & numerical data).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- chemical , supply & distribution : Influenza Vaccines.
- adverse effects : Vaccination.
- prevention & control : Influenza, Human, Pregnancy Complications, Infectious.
- statistics & numerical data : Vaccination.
- Canada, Female, Health Services Accessibility, Humans, Pregnancy, Prenatal Care, Risk Assessment, Safety, Treatment Outcome, United States.
Abstract
Pregnant women have an increased risk of influenza infection and complications. The Advisory Committee on Immunization Practices currently recommends vaccination for women who are pregnant during influenza season. The authors review the literature concerning influenza vaccine safety, effectiveness, and coverage rates during pregnancy, as well as opportunities to improve vaccination rates during pregnancy. No study has demonstrated an increased risk of maternal complications or adverse fetal outcomes associated with inactivated influenza vaccine. Few studies have examined the effectiveness of vaccination during pregnancy, and the results from these studies are inconsistent, with some showing a protective effect and others showing no effect. Despite the proven safety of vaccination and the possible benefits to women and their infants, reported vaccination rates during pregnancy are generally less than 10%. Mothers frequently cite concerns about vaccine safety as a barrier to vaccination. Lack of adequate information about the risks and benefits of vaccination is reported by both patients and obstetric care providers. Organizational factors such as lack of vaccine storage facilities may also limit vaccination during pregnancy. Effective interventions should target factors pertaining to patients or providers, or they should address organizational or logistic barriers. The Advisory Committee on Immunization Practices currently recommends standing orders programs or reminders for patients and providers as strategies to improve vaccination rates.
DOI: 10.1093/epirev/mxj002
PubMed: 16731574
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Delivering influenza vaccine to pregnant women.</title><author><name sortKey="Naleway, Allison L" sort="Naleway, Allison L" uniqKey="Naleway A" first="Allison L" last="Naleway">Allison L. Naleway</name><affiliation wicri:level="2"><nlm:affiliation>Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227, USA. allison.naleway@kpchr.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Smith, Wendy J" sort="Smith, Wendy J" uniqKey="Smith W" first="Wendy J" last="Smith">Wendy J. Smith</name></author><author><name sortKey="Mullooly, John P" sort="Mullooly, John P" uniqKey="Mullooly J" first="John P" last="Mullooly">John P. Mullooly</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16731574</idno><idno type="pmid">16731574</idno><idno type="doi">10.1093/epirev/mxj002</idno><idno type="wicri:Area/Main/Corpus">000913</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000913</idno><idno type="wicri:Area/Main/Curation">000913</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000913</idno><idno type="wicri:Area/Main/Exploration">000913</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Delivering influenza vaccine to pregnant women.</title><author><name sortKey="Naleway, Allison L" sort="Naleway, Allison L" uniqKey="Naleway A" first="Allison L" last="Naleway">Allison L. Naleway</name><affiliation wicri:level="2"><nlm:affiliation>Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227, USA. allison.naleway@kpchr.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Smith, Wendy J" sort="Smith, Wendy J" uniqKey="Smith W" first="Wendy J" last="Smith">Wendy J. Smith</name></author><author><name sortKey="Mullooly, John P" sort="Mullooly, John P" uniqKey="Mullooly J" first="John P" last="Mullooly">John P. Mullooly</name></author></analytic><series><title level="j">Epidemiologic reviews</title><idno type="ISSN">0193-936X</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Canada</term><term>Female</term><term>Health Services Accessibility</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (supply & distribution)</term><term>Influenza, Human (prevention & control)</term><term>Pregnancy</term><term>Pregnancy Complications, Infectious (prevention & control)</term><term>Prenatal Care</term><term>Risk Assessment</term><term>Safety</term><term>Treatment Outcome</term><term>United States</term><term>Vaccination (adverse effects)</term><term>Vaccination (statistics & numerical data)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accessibilité des services de santé</term><term>Canada</term><term>Complications de la grossesse et maladies infectieuses ()</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grossesse</term><term>Humains</term><term>Prise en charge prénatale</term><term>Résultat thérapeutique</term><term>Sécurité</term><term>Vaccination ()</term><term>Vaccination (effets indésirables)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (ressources et distribution)</term><term>États-Unis d'Amérique</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Canada</term><term>Female</term><term>Health Services Accessibility</term><term>Humans</term><term>Pregnancy</term><term>Prenatal Care</term><term>Risk Assessment</term><term>Safety</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Accessibilité des services de santé</term><term>Canada</term><term>Complications de la grossesse et maladies infectieuses</term><term>Femelle</term><term>Grippe humaine</term><term>Grossesse</term><term>Humains</term><term>Prise en charge prénatale</term><term>Résultat thérapeutique</term><term>Sécurité</term><term>Vaccination</term><term>États-Unis d'Amérique</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pregnant women have an increased risk of influenza infection and complications. The Advisory Committee on Immunization Practices currently recommends vaccination for women who are pregnant during influenza season. The authors review the literature concerning influenza vaccine safety, effectiveness, and coverage rates during pregnancy, as well as opportunities to improve vaccination rates during pregnancy. No study has demonstrated an increased risk of maternal complications or adverse fetal outcomes associated with inactivated influenza vaccine. Few studies have examined the effectiveness of vaccination during pregnancy, and the results from these studies are inconsistent, with some showing a protective effect and others showing no effect. Despite the proven safety of vaccination and the possible benefits to women and their infants, reported vaccination rates during pregnancy are generally less than 10%. Mothers frequently cite concerns about vaccine safety as a barrier to vaccination. Lack of adequate information about the risks and benefits of vaccination is reported by both patients and obstetric care providers. Organizational factors such as lack of vaccine storage facilities may also limit vaccination during pregnancy. Effective interventions should target factors pertaining to patients or providers, or they should address organizational or logistic barriers. The Advisory Committee on Immunization Practices currently recommends standing orders programs or reminders for patients and providers as strategies to improve vaccination rates.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16731574</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0193-936X</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Epidemiologic reviews</Title><ISOAbbreviation>Epidemiol Rev</ISOAbbreviation></Journal><ArticleTitle>Delivering influenza vaccine to pregnant women.</ArticleTitle><Pagination><MedlinePgn>47-53</MedlinePgn></Pagination><Abstract><AbstractText>Pregnant women have an increased risk of influenza infection and complications. The Advisory Committee on Immunization Practices currently recommends vaccination for women who are pregnant during influenza season. The authors review the literature concerning influenza vaccine safety, effectiveness, and coverage rates during pregnancy, as well as opportunities to improve vaccination rates during pregnancy. No study has demonstrated an increased risk of maternal complications or adverse fetal outcomes associated with inactivated influenza vaccine. Few studies have examined the effectiveness of vaccination during pregnancy, and the results from these studies are inconsistent, with some showing a protective effect and others showing no effect. Despite the proven safety of vaccination and the possible benefits to women and their infants, reported vaccination rates during pregnancy are generally less than 10%. Mothers frequently cite concerns about vaccine safety as a barrier to vaccination. Lack of adequate information about the risks and benefits of vaccination is reported by both patients and obstetric care providers. Organizational factors such as lack of vaccine storage facilities may also limit vaccination during pregnancy. Effective interventions should target factors pertaining to patients or providers, or they should address organizational or logistic barriers. The Advisory Committee on Immunization Practices currently recommends standing orders programs or reminders for patients and providers as strategies to improve vaccination rates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naleway</LastName><ForeName>Allison L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227, USA. allison.naleway@kpchr.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Wendy J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Mullooly</LastName><ForeName>John P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epidemiol Rev</MedlineTA><NlmUniqueID>7910703</NlmUniqueID><ISSNLinking>0193-936X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Epidemiol. 2007 Feb 1;165(3):351-2; author reply 352-3</RefSource><PMID Version="1">17158476</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011295" MajorTopicYN="Y">Prenatal Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>44</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16731574</ArticleId><ArticleId IdType="pii">mxj002</ArticleId><ArticleId IdType="doi">10.1093/epirev/mxj002</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Oregon</li></region></list><tree><noCountry><name sortKey="Mullooly, John P" sort="Mullooly, John P" uniqKey="Mullooly J" first="John P" last="Mullooly">John P. Mullooly</name><name sortKey="Smith, Wendy J" sort="Smith, Wendy J" uniqKey="Smith W" first="Wendy J" last="Smith">Wendy J. Smith</name></noCountry><country name="États-Unis"><region name="Oregon"><name sortKey="Naleway, Allison L" sort="Naleway, Allison L" uniqKey="Naleway A" first="Allison L" last="Naleway">Allison L. Naleway</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000865 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000865 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16731574
|texte= Delivering influenza vaccine to pregnant women.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16731574" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |